Clinical trials: Pneumococcal Infection
Pneumonia, Bacterial
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study
- Trial name
- NCT07406347
- Testing
- Pn-MAPS30plus, PCV20
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
The primary aim of this study is to assess the reactogenicity of Synflorix vaccine and Prevenar 13 vaccine after primary vaccination at 2 and 4 months of age with either Synflorix or Prevenar 13 vaccine or Prevenar 13 and…
- Trial name
- NCT01641133
- Testing
- Synflorix (3-Dose), Synflorix (2-Dose), Synflorix (Single Dose)
- Where
- 3 sites in Mexico
- Volunteers
- 457 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Invasive Pneumococcic
Identification and Quantification of Immune Response Induced by Hyaluronidase and Other Factors of Virulence of Invasive Human Infections of Streptococcus Pneumoniae
4 tubes (2 x7-ml dry tubes with yellow gelose, and 2 x 5 ml tubes with blue CTAD) will be taken from the patient within 24 hours following inclusion (D0) in the department in which the patient is hospitalised 4 tubes (2 x7-ml dry…
- Trial name
- Hyalo strepto (NCT01931800)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 135 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Pathogen Resistance, Pneumococcal Infection
Aerosolized and Intravenous Colistin in Healthy Adults
Colistin is amphipathic, cannot be absorbed from the gastrointestinal tract and is administered intramuscularly, intravenously (IV) or via inhalation.
- Conditions
- Pathogen Resistance, Pneumococcal Infection, Pneumonia
- Trial name
- NCT01863719
- Testing
- Colistimethate sodium
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Pneumococcal
Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
The purpose of this study is to compare levofloxacin vs ceftriaxone impact on the cytokine production in patients with pneumococcal pneumonia.
- Trial name
- NCT00429975
- Testing
- levofloxacin, ceftriaxone
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Hospital Mutua de Terrassa
Pneumococcal Infections
Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine
This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should be naïve of Pneumococcal vaccine.
- Trial name
- NCT02079207
- Testing
- NBP606, Prodiax-23
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
HIV Infections
Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults
The purpose of this study is to determine whether TLR-9 adjuvanted pneumococcal is more immunogenic than pneumococcal vaccination alone in HIV-infected adults.
- Trial name
- ITAP (NCT00562939)
- Testing
- Pneumococcal vaccines + CPG 7909, Pneumococcal vaccines
- Where
- Denmark
- Volunteers
- 97 people
- Sponsor
- University of Aarhus
Pneumococcal Infection
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as…
- Trial name
- STRIDE-13 (NCT06177912)
- Testing
- V116, PPSV23
- Where
- 92 sites in United States, Canada and 11 more
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Varicella, Rubella
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
The purpose of this observer blinded study is to provide information on vaccine immunogenicity and reactogenicity in comparison with the US standard of care (ProQuad®) when administered with Hepatitis A vaccine and Pneumococcal…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00578175
- Testing
- Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix®
- Where
- 141 sites in United States
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Otitis Media
Host-pathogen Interaction in Otitis Media
Otitis Media (OM) is one of the most frequent diseases in childhood and the primary reason for children to visit a physician. In many countries it is the most common reason to prescribe antibiotics leading to increased…
- Trial name
- OMVac (NCT00847756)
- Testing
- questionnaire, blood sample, collection of middle ear fluid
- Where
- 2 sites in Netherlands
- Volunteers
- 179 people
- Sponsor
- Radboud University Medical Center
Pneumococcal Infections
Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
This study is being conducted to evaluate the safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine (V114) compared to Prevnar™ in healthy adults and toddlers.
- Trial name
- NCT01215175
- Testing
- Prevnar™, V114, Aluminum Adjuvanted, V114, Aluminum Nonadjuvanted
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Streptococcal
Evaluation of Pneumococcal Vaccine Formulations in Elderly
The purpose of this observer-blind study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in elderly. Subjects will be vaccinated twice with an interval of two months.
- Trial name
- NCT00756067
- Testing
- Pneumococcal vaccine GSK2189241A, Pneumo 23™
- Where
- 3 sites in Sweden
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia
Pneumococcal Adult-dose Ranging Immunization Study
The purpose of this study is to give seniors different doses of a new pneumococcal vaccine called PCV7 to evaluate the safety of the vaccine and compare the immune response to find out which amount gives the best immune response.
- Trial name
- NCT00169234
- Testing
- PCV7, Prevnar®, Pneumovax 23
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Kaiser Permanente
Otitis Media
Effect of Prevnar 13 on Ear Infections in Children
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar.
- Trial name
- NCT01199016
- Testing
- Tympanocentesis, Nose/throat swab, Observational
- Where
- 7 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Infections, Streptococcal
Evaluation of Pneumococcal Vaccine Formulations in Young Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in young adults. Subjects will be vaccinated twice with an interval of two months.
- Trial name
- NCT00707798
- Testing
- Pneumococcal vaccine GSK2189242A, Pneumo 23™
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Asthma
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
Goal: to to examine the formation of postvaccination immunity and evaluate the therapeutic effect of bacterial vaccines in patients with inflammation diseases of bronchopulmonary system.
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Pneumococcal Infections
- Trial name
- NCT02787863
- Testing
- Prevenar-13, Pneumo-23
- Where
- 2 sites in Russia
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Mikhael Petrovich Kostinov
Community Acquired Pneumonia (CAP)
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.
- Trial name
- NCT04613375
- Testing
- Urine sample collection, Saliva collection
- Where
- 5 sites in Spain
- Volunteers
- 1,821 people
- Sponsor
- Pfizer
Pneumococcal Disease
Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines
This is an open-label phase III clinical trial. The purpose of this trial is to investigate in detail the kinetics of the immune response to Prevenar-13, a pneumococcal conjugate vaccine, compared to Pneumovax-II, a pneumococcal…
- Trial name
- NCT01432158
- Testing
- Prevenar 13, Pneumovax II
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pneumococcal Disease
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults…
- Trial name
- NCT07284654
- Testing
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Where
- 30 sites in United States
- Volunteers
- 4,049 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Infections
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
This is a Phase 2, randomized, active-controlled, open-label study with a 3-arm parallel design. Healthy 2-month old infants (42 to 98 days of age) with no history of pneumococcal vaccination will be randomized in a 1:1:1 ratio…
- Trial name
- NCT03550313
- Testing
- Multivalent, Prevnar 13
- Where
- 48 sites in United States
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- Pfizer